Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett’s Esophagus: A Systematic Review and Meta-Analysis

Objectives Proton pump inhibitors (PPIs) have been used for treatment of Barrett's esophagus (BE) for many years. However, the connection between PPIs and esophageal adenocarcinoma (EAC) in patients with BE has still been controversial. The current systematic review and meta-analysis was designed to evaluate the association between PPIs and the risk of EAC or high-grade dysplasia (HGD) in patients with BE. Methods A systematic literature search of studies reporting the association between PPIs and the risk of EAC and/or HGD in patients with BE was conducted in PubMed, Embase, Web of Science and the Cochrane Library. Next, literature was screened using previously established criteria and relevant data were extracted from included studies. Finally, the software program Review Manage 5.2 was applied to aggregate data and analyze the results. Results Nine observational studies, comprising five cohort and four case-control studies (including a total of 5712 patients with BE), were identified. Upon meta-analysis, PPIs were found to have no association with the risk of EAC and/or HGD in patients with BE (unadjusted OR 0.43, 95% CI 0.17–1.08). Analysis for duration response relationship revealed no significant trend toward protection against EAC or HGD with PPIs usage for >2~3 years (one study using 7-year cutoff) when compared to usage for shorter time periods (PPIs usage >2~3 years vs. <2~3 years: OR 0.91 (95% CI 0.25–3.31) vs. 0.91 (0.40–2.07)).There also was considerable heterogeneity between studies. Conclusion No dysplasia- or cancer-protective effects of PPIs usage in patients with BE were identified by our analysis. Therefore, we conclude that clinicians who discuss the potential chemopreventive effects of PPIs with their patients, should be aware that such an effect, if exists, has not been proven with statistical significance.

[1]  V. Choubey,et al.  Lansoprazole Protects and Heals Gastric Mucosa from Non-steroidal Anti-inflammatory Drug (NSAID)-induced Gastropathy by Inhibiting Mitochondrial as Well as Fas-mediated Death Pathways with Concurrent Induction of Mucosal Cell Renewal* , 2008, Journal of Biological Chemistry.

[2]  A. Lindgren,et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.

[3]  C. Lightdale,et al.  Correlation between serum gastrin and cellular proliferation in Barrett’s esophagus , 2011, Therapeutic advances in gastroenterology.

[4]  V. Choubey,et al.  Withdrawal: Lansoprazole protects and heals gastric mucosa from non-steroidal anti-inflammatory drug (NSAID)-induced gastropathy by inhibiting mitochondrial as well as Fas-mediated death pathways with concurrent induction of mucosal cell renewal. , 2008, The Journal of Biological Chemistry.

[5]  W. Tsai,et al.  Elevated Serum Gastrin Is Associated With a History of Advanced Neoplasia in Barrett's Esophagus , 2010, The American Journal of Gastroenterology.

[6]  S. Meltzer,et al.  Advances in Brief Increased Expression of Inducible Nitric Oxide Synthase and Cyclooxygenase-2 in Barrett ' s Esophagus and Associated Adenocarcinomas 1 , 2006 .

[7]  J. Lagergren,et al.  Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK , 2006, Gut.

[8]  B. Shadbolt,et al.  Proton‐pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus , 2004, The Medical journal of Australia.

[9]  Jonathan A C Sterne,et al.  Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. , 2001, BMJ.

[10]  A. Oluwasanmi,et al.  Gastro-oesophageal reflux disease. , 1999, Hospital medicine.

[11]  A. Neugut,et al.  Dating the Rise of Esophageal Adenocarcinoma: Analysis of Connecticut Tumor Registry Data, 1940–2007 , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[12]  A. Bhattacharyya,et al.  Medication usage and the risk of neoplasia in patients with Barrett's esophagus. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  Samy Suissa,et al.  Time-window bias in case-control studies: statins and lung cancer. , 2011, Epidemiology.

[14]  Prateek Sharma,et al.  American Gastroenterological Association medical position statement on the management of Barrett's esophagus. , 2011, Gastroenterology.

[15]  B. Reid,et al.  Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis , 2010, Nature Reviews Cancer.

[16]  D. Forman,et al.  Dyspeptic Symptoms and Endoscopic Findings in the Community: The Loiano–Monghidoro Study , 2010, The American Journal of Gastroenterology.

[17]  E. Kuipers,et al.  Role of Acid Suppression in the Development and Progression of Dysplasia in Patients with Barrett’s Esophagus , 2011, Digestive Diseases.

[18]  E. Kuipers,et al.  Risk Factors for the Development of Esophageal Adenocarcinoma in Barrett's Esophagus , 2006, The American Journal of Gastroenterology.

[19]  T. Okanoue,et al.  Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors , 2006, Inflammation Research.

[20]  S. Spechler,et al.  Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-κB activation in benign Barrett's epithelial cells. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[21]  P. Downey,et al.  Acid suppression increases rates of Barrett's esophagus and esophageal injury in the presence of duodenal reflux. , 2012, Surgery.

[22]  Peter J. Richardson,et al.  Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. , 2010, Gastroenterology.

[23]  Samy Suissa,et al.  Immortal time bias in observational studies of drug effects , 2007, Pharmacoepidemiology and drug safety.

[24]  E. Kuipers,et al.  Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  A. Clark,et al.  Statin use is associated with reduced risk of histologic subtypes of esophageal cancer: a nested case-control analysis. , 2014, Gastroenterology.

[26]  H. El‐Serag,et al.  Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis , 2013, Gut.

[27]  P. Funch‐jensen,et al.  Proton pump inhibitor use may not prevent high‐grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients , 2014, Alimentary pharmacology & therapeutics.

[28]  H. Welch,et al.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. , 2005, Journal of the National Cancer Institute.

[29]  Kenneth K Wang,et al.  The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. , 2002, Journal of the National Cancer Institute.

[30]  E. Kuipers.  Barrett's oesophagus, proton pump inhibitors and gastrin: the fog is clearing , 2010, Gut.

[31]  D. Thompson,et al.  Gastrin induces proliferation in Barrettʼs metaplasia through activation of the CCK2 receptor , 2003 .

[32]  H. Matsui,et al.  Lansoprazole, a Proton Pump Inhibitor, Mediates Anti-Inflammatory Effect in Gastric Mucosal Cells through the Induction of Heme Oxygenase-1 via Activation of NF-E2-Related Factor 2 and Oxidation of Kelch-Like ECH-Associating Protein 1 , 2009, Journal of Pharmacology and Experimental Therapeutics.

[33]  W. Chow,et al.  Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. , 2008, Journal of the National Cancer Institute.

[34]  A. Dobrian,et al.  Proton Pump Inhibitors: The Culprit for Barrett’s Esophagus? , 2015, Front. Oncol..

[35]  Furhawn A. Shah,et al.  Do proton pump inhibitors protect against cancer progression in GERD? , 2013, Surgery Today.

[36]  E. Kuipers,et al.  NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case–control study , 2015, BMJ Open.

[37]  N. Snyder,et al.  Prevalence of Barrett’s Esophagus in Patients with or without GERD Symptoms: Role of Race, Age, and Gender , 2009, Digestive Diseases and Sciences.

[38]  A. Stang.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.

[39]  P. Funch‐jensen,et al.  Proximal and distal esophageal sensitivity is decreased in patients with Barrett's esophagus. , 2011, World journal of gastroenterology.

[40]  M. Rugge,et al.  Role of Proton Pump Inhibitor on Esophageal Carcinogenesis and Pancreatic Acinar Cell Metaplasia Development: An Experimental In Vivo Study , 2014, PloS one.

[41]  N. Marcon,et al.  A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. , 2012, Gastroenterology.

[42]  Rebecca C Fitzgerald,et al.  British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus , 2013, Gut.

[43]  A. Zinsmeister,et al.  Epidemiology and Natural History of Intestinal Metaplasia of the Gastroesophageal Junction and Barrett's Esophagus: A Population-Based Study , 2011, The American Journal of Gastroenterology.

[44]  W. Garnett.  History of Acid Suppression: Focus on the Hospital Setting , 2003, Pharmacotherapy.

[45]  P. Funch‐jensen,et al.  Letter: proton pump inhibitor usage still seems to reduce the risk of high‐grade dysplasia and/or oesophageal adenocarcinoma in Barrett's oesophagus – authors’ reply , 2014, Alimentary pharmacology & therapeutics.